View in EDS HTML Full Text PDF Full Text

Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study.

Saved in:
Bibliographic Details
Title: Ultralow Prostate-Specific Antigen (PSA) Levels and Improved Oncological Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Treated with Apalutamide: A Real-World Multicentre Study.
Authors: López-Abad, Alicia1 (AUTHOR) alicialopezabad@gmail.com, Belmonte, Mario2 (AUTHOR), Ramírez Backhaus, Miguel3 (AUTHOR), Server Gómez, Gerardo4 (AUTHOR), Cao Avellaneda, Enrique1 (AUTHOR), Moreno Alarcón, Cristóbal1 (AUTHOR), López Cubillana, Pedro1 (AUTHOR), Yago Giménez, Pablo1 (AUTHOR), de Pablos Rodríguez, Pedro3 (AUTHOR), Juan Fita, María José3 (AUTHOR), Climent Durán, Miguel Ángel3 (AUTHOR), Guardiola Ruiz, Iris4 (AUTHOR), Vidal Crespo, Natalia4 (AUTHOR), Moreno Avilés, Juan4 (AUTHOR), Guzmán Martínez-Valls, Pablo Luis1 (AUTHOR), López González, Pedro Ángel1 (AUTHOR)
Source: Journal of Clinical Medicine. Oct2024, Vol. 13 Issue 20, p6221. 10p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20770383
DOI:10.3390/jcm13206221